Option Care Health, Inc. (OPCH) AI Stock Analysis

Option Care Health, Inc. specializes in delivering home and alternate site infusion services across the United States. Its clinical offerings cover therapies for acute and chronic conditions, such as anti-infective treatments, heart failure management, and parenteral nutrition support for stroke, cancer, and gastrointestinal illnesses. It also provides immunoglobulin infusions for immune deficiencies, chronic inflammatory condition treatments (including Crohn's disease, psoriasis, and arthritis), and therapies for neurological conditions like ALS and Duchenne muscular dystrophy. Additional services include care for bleeding disorders, high-risk pregnancies, pain management, chemotherapy, and respiratory care, backed by a clinical nursing team.

Option Care Health grew revenue from $3.44B in FY2021 to $5.65B in FY2025, posting a 5-year revenue CAGR of 13.3%. Net income increased from $139.9M in FY2021 to a peak of $267.1M in FY2023, before dropping to $207.6M in FY2025. Gross margins contracted from 22.7% in FY2021 to 18.1% in FY2025, while operating margins moved from 5.5% to 6.0%. Diluted EPS rose to $1.72 in FY2025. Over the trailing twelve months, revenue reached $5.69B with a profit margin of 3.7%. For the latest quarter ended June 30, 2026, revenue increased 1.9% year-over-year while quarterly earnings expanded 12.9%.

As of June 30, 2026, Option Care Health held $193.8M in cash and short-term investments alongside $1.27B in total debt, resulting in net debt of $1.07B. Total assets stood at $3.38B against shareholders' equity of $1.26B, yielding a debt-to-equity ratio of 1.01 and a current ratio of 1.47. In FY2025, operating cash flow was $258.4M and free cash flow reached $217.1M. Capital expenditures were $41.3M, while the company directed $310.0M to share buybacks, lowering its share count by 15.4% over five years.

At $31.20, Option Care Health trades at a trailing P/E of 23.6x and a forward P/E of 11.2x, below the US-listed Healthcare median forward P/E of 17.3x. Its EV/EBITDA multiple is 11.1x versus the sector peer median of 12.0x, and its price-to-sales multiple is 0.8x compared to the peer median of 4.1x. Over the past year, the stock returned 15.1%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, the stock gained 27.6%, lagging the index return of 83.0%.

Wall Street sentiment is neutral, with all 11 covering analysts assigning a Hold rating. The mean price target of $30.03 sits 3.7% below the last close of $31.20. Consensus estimates project FY2026 revenue of $5.76B and EPS of $1.88, reflecting 9.4% earnings growth. For FY2027, 11 analysts estimate revenue of $6.13B and EPS of $2.08. Option Care Health beat EPS estimates in 3 of the last 4 quarters, and its next earnings release is scheduled for October 29, 2026.

This page is an AI-written research summary of Option Care Health, Inc. (OPCH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OPCH income statement, OPCH balance sheet, OPCH key metrics, OPCH analyst forecast, OPCH chart. See the OPCH stock overview for the latest quote and news.